BACKGROUND: Soluble ST2 (sST2) is a cardiac biomarker whose concentration rises in response to myocardial strain. Increased sST2 concentrations may predict adverse outcomes in patients with heart failure and myocardial infarction. Because sST2 was largely undetectable with first-generation assays in ambulatory individuals, there are few data regarding its distribution and correlates in community-based populations. METHODS: We measured sST2 using a highly sensitive ELISA in 3450 Framingham Heart Study participants who attended a routine examination. We used multivariable linear regression models to identify covariates associated with sST2 in the general sample. We obtained a reference sample (n = 1136) by excluding individuals with prevalent coronary disease, heart failure, atrial fibrillation, diabetes, hypertension, obesity, valvular disease, left ventricular systolic dysfunction, and pulmonary and renal dysfunction. We used empiric and quantile regression techniques to estimate the 2.5th, 50th, 97.5th, and 99th quantiles. RESULTS: In the general sample (mean age 59 years, 55% women), systolic blood pressure (P = 0.006), antihypertensive medication use (P = 0.03), and diabetes (P < 0.001) were associated with sST2 concentrations. In the reference sample (mean age 55, 59% women), male sex (P < 0.0001) and older age (P = 0.004) were predictive of higher sST2 concentrations. Quantile and empirical methods were used to define the reference intervals. Using the empirical approach, upper 99% percentile values in different age groups ranged from 46.6 to 64.4 μg/L in men and 36.7 to 53.0 μg/L in women. CONCLUSIONS: In a well-characterized, community-based cohort, values for sST2 differ between men and women, increase with age, and are associated with diabetes and hypertension.
BACKGROUND: Soluble ST2 (sST2) is a cardiac biomarker whose concentration rises in response to myocardial strain. Increased sST2 concentrations may predict adverse outcomes in patients with heart failure and myocardial infarction. Because sST2 was largely undetectable with first-generation assays in ambulatory individuals, there are few data regarding its distribution and correlates in community-based populations. METHODS: We measured sST2 using a highly sensitive ELISA in 3450 Framingham Heart Study participants who attended a routine examination. We used multivariable linear regression models to identify covariates associated with sST2 in the general sample. We obtained a reference sample (n = 1136) by excluding individuals with prevalent coronary disease, heart failure, atrial fibrillation, diabetes, hypertension, obesity, valvular disease, left ventricular systolic dysfunction, and pulmonary and renal dysfunction. We used empiric and quantile regression techniques to estimate the 2.5th, 50th, 97.5th, and 99th quantiles. RESULTS: In the general sample (mean age 59 years, 55% women), systolic blood pressure (P = 0.006), antihypertensive medication use (P = 0.03), and diabetes (P < 0.001) were associated with sST2 concentrations. In the reference sample (mean age 55, 59% women), male sex (P < 0.0001) and older age (P = 0.004) were predictive of higher sST2 concentrations. Quantile and empirical methods were used to define the reference intervals. Using the empirical approach, upper 99% percentile values in different age groups ranged from 46.6 to 64.4 μg/L in men and 36.7 to 53.0 μg/L in women. CONCLUSIONS: In a well-characterized, community-based cohort, values for sST2 differ between men and women, increase with age, and are associated with diabetes and hypertension.
Authors: Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray Journal: J Am Coll Cardiol Date: 2010-01-19 Impact factor: 24.094
Authors: Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis Journal: J Am Coll Cardiol Date: 2009-12-01 Impact factor: 24.094
Authors: Nemanja Zdravkovic; Allen Shahin; Nebojsa Arsenijevic; Miodrag L Lukic; Eric P K Mensah-Brown Journal: Mol Immunol Date: 2009-04-07 Impact factor: 4.407
Authors: Jozef Bartunek; Leen Delrue; Frederik Van Durme; Olivier Muller; Filip Casselman; Bart De Wiest; Romaric Croes; Sofie Verstreken; Marc Goethals; Herbert de Raedt; Jaydeep Sarma; Lija Joseph; Marc Vanderheyden; Ellen O Weinberg Journal: J Am Coll Cardiol Date: 2008-12-16 Impact factor: 24.094
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino Journal: Circulation Date: 2003-03-25 Impact factor: 29.690
Authors: Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang Journal: J Clin Invest Date: 2013-09-03 Impact factor: 14.808
Authors: Jessica C Garbern; Jason Williams; Amy C Kristl; Alyyah Malick; Inbal Rachmin; Benjamin Gaeta; Nafis Ahmed; Ana Vujic; Peter Libby; Richard T Lee Journal: J Mol Cell Cardiol Date: 2019-02-11 Impact factor: 5.000
Authors: Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon Journal: Circ Heart Fail Date: 2016-01 Impact factor: 8.790
Authors: William S Jenkins; Véronique L Roger; Allan S Jaffe; Susan A Weston; Omar F AbouEzzeddine; Ruoxiang Jiang; Sheila M Manemann; Maurice Enriquez-Sarano Journal: Am J Med Date: 2017-03-23 Impact factor: 4.965